miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

BACKGROUND: While the treatment of HER2 over-expressing breast cancer with recent HER-targeted drugs has been highly effective for some patients, primary (also known as innate) or acquired resistance limits the success of these drugs. microRNAs have potential as diagnostic, prognostic and predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Corcoran, Claire, Rani, Sweta, Breslin, Susan, Gogarty, Martina, Ghobrial, Irene M, Crown, John, O’Driscoll, Lorraine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234346/
https://www.ncbi.nlm.nih.gov/pubmed/24655723
http://dx.doi.org/10.1186/1476-4598-13-71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234346/
https://www.ncbi.nlm.nih.gov/pubmed/24655723
http://dx.doi.org/10.1186/1476-4598-13-71

Ejemplares similares